About Arbutus Biopharma Corporation (NASDAQ:ABUS)
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ABUS
- CUSIP: N/A
- Web: www.arbutusbio.com
Capitalization:- Market Cap: $352.17 million
- Outstanding Shares: 55,026,000
Average Prices:- 50 Day Moving Avg: $6.17
- 200 Day Moving Avg: $4.21
- 52 Week Range: $2.35 - $8.25
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.61
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.85 million
- Price / Sales: 193.33
- Book Value: $3.19 per share
- Price / Book: 2.04
Profitability:- EBITDA: ($65,740,000.00)
- Return on Equity: -28.97%
- Return on Assets: -21.71%
Debt:- Debt-to-Equity Ratio: 0.07%
- Current Ratio: 8.92%
- Quick Ratio: 8.92%
Misc:- Average Volume: 321,092 shs.
- Beta: 1.01
- Short Ratio: 9.83
Frequently Asked Questions for Arbutus Biopharma Corporation (NASDAQ:ABUS)
What is Arbutus Biopharma Corporation's stock symbol?
Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma Corporation's earnings last quarter?
Arbutus Biopharma Corporation (NASDAQ:ABUS) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.11. The business had revenue of $4.10 million for the quarter, compared to analysts' expectations of $3.37 million. View Arbutus Biopharma Corporation's Earnings History.
When will Arbutus Biopharma Corporation make its next earnings announcement?
Where is Arbutus Biopharma Corporation's stock going? Where will Arbutus Biopharma Corporation's stock price be in 2017?
5 equities research analysts have issued 12-month price targets for Arbutus Biopharma Corporation's stock. Their forecasts range from $6.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Arbutus Biopharma Corporation.
What are analysts saying about Arbutus Biopharma Corporation stock?
Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:
- 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (7/10/2017)
- 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)
Who are some of Arbutus Biopharma Corporation's key competitors?
Some companies that are related to Arbutus Biopharma Corporation include ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), ImmunoGen (IMGN), WAVE Life Sciences (WVE), Voyager Therapeutics (VYGR), Celyad SA (CYAD), Mesoblast Limited (MESO), Inovio Pharmaceuticals (INO), PDL BioPharma (PDLI), TG Therapeutics (TGTX), Agenus (AGEN), Adamas Pharmaceuticals (ADMS), Kala Pharmaceuticals (KALA), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE), Idera Pharmaceuticals (IDRA) and Codexis (CDXS).
Who are Arbutus Biopharma Corporation's key executives?
Arbutus Biopharma Corporation's management team includes the folowing people:
- Vivek Ramaswamy, Chairman of the Board
- Mark J. Murray Ph.D., President, Chief Executive Officer, Director
- Bruce G. Cousins, Chief Financial Officer, Executive Vice President
- Elizabeth Howard, Executive Vice President, General Counsel
- Peter Lutwyche Ph.D., Chief Technology Officer
- Michael Joseph Sofia, Chief Scientific Officer
- William Thomas Symonds III, Chief Development Officer, Director
- Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets
- Patrick T. Higgins, Chief Business Officer
- Daniel D. Burgess, Director
How do I buy Arbutus Biopharma Corporation stock?
Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arbutus Biopharma Corporation's stock price today?
One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $6.50.
MarketBeat Community Rating for Arbutus Biopharma Corporation (NASDAQ ABUS)MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)Earnings History by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.37) | | | | | N/A |  |
| 5/4/2017 | 3/31/2017 | ($0.30) | ($0.34) | $7.50 million | $0.20 million | View | Listen | |
| 11/5/2015 | Q3 2015 | ($0.31) | ($0.42) | $3.37 million | $4.10 million | View | N/A | |
| 8/5/2015 | Q2 | ($0.25) | ($0.20) | $3.77 million | $3.40 million | View | N/A | |
| 3/12/2015 | Q4 2014 | ($0.32) | ($0.27) | $6.12 million | $4.40 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.40) | ($0.39) | $3.71 million | $4.40 million | View | N/A | |
| 8/14/2014 | Q214 | ($0.13) | ($0.11) | $3.72 million | $1.80 million | View | N/A | |
| 12/18/2013 | Q3 | ($0.07) | ($0.12) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Arbutus Biopharma Corporation (NASDAQ:ABUS)2017 EPS Consensus Estimate: ($1.54)
2018 EPS Consensus Estimate: ($1.53)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | ($0.38) | ($0.25) | ($0.30) |
| Q2 2017 | 3 | ($0.42) | ($0.39) | ($0.40) |
| Q3 2017 | 3 | ($0.43) | ($0.39) | ($0.41) |
| Q4 2017 | 3 | ($0.44) | ($0.39) | ($0.42) |
| Q1 2018 | 2 | ($0.38) | ($0.36) | ($0.37) |
| Q2 2018 | 2 | ($0.39) | ($0.36) | ($0.38) |
| Q3 2018 | 2 | ($0.40) | ($0.37) | ($0.39) |
| Q4 2018 | 2 | ($0.41) | ($0.38) | ($0.40) |
(Data provided by Zacks Investment Research)
Dividend History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Arbutus Biopharma Corporation (NASDAQ:ABUS)Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 67.04%
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/3/2017 | Michael J Sofia | Insider | Sell | 10,000 | $8.00 | $80,000.00 | |
| 8/15/2017 | Michael J Sofia | Insider | Sell | 30,000 | $3.70 | $111,000.00 | |
| 8/24/2015 | Richard C Henriques Jr | Director | Buy | 1,000 | $6.95 | $6,950.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Latest Headlines for Arbutus Biopharma Corporation (NASDAQ:ABUS)
| Source: |
|
| Date | Headline |
|---|
 | Arbutus out-licenses LNP technology to Gritstone Oncology - Seeking Alpha
seekingalpha.com - October 18 at 3:42 PM |
 | Arbutus Biopharma (ABUS) and Gritstone Oncology Reports LNP ... - StreetInsider.com
www.streetinsider.com - October 18 at 3:42 PM |
 | Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
finance.yahoo.com - October 18 at 3:42 PM |
| Bucks biopharm firm signs licensing deal with California onco-immunology company
finance.yahoo.com - October 18 at 3:42 PM |
 | Arbutus Biopharma Corporation (ABUS) Expected to Post Quarterly Sales of $790,000.00
www.americanbankingnews.com - October 17 at 6:50 AM |
 | Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences - GlobeNewswire (press release)
globenewswire.com - October 16 at 3:32 PM |
| Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 16 at 3:32 PM |
| Contrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)
www.americanbankingnews.com - October 16 at 10:58 AM |
| Arbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - October 15 at 2:24 PM |
| Arbutus Biopharma Corporation (ABUS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 4:46 PM |
| Insider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - October 5 at 7:44 PM |
 | Arbutus Biopharma Corp. (ABUS) Has Broken Out To A New High For The Year
www.rttnews.com - October 4 at 3:10 PM |
| JMP Securities Reaffirms "Outperform" Rating for Arbutus Biopharma Corporation (ABUS)
www.americanbankingnews.com - October 4 at 1:42 PM |
| Arbutus Biopharma Corporation to Post Q1 2018 Earnings of ($0.38) Per Share, Wedbush Forecasts (ABUS)
www.americanbankingnews.com - October 4 at 11:04 AM |
| Arbutus Biopharma: Updates To Thesis Part 2 - Seeking Alpha
seekingalpha.com - October 4 at 8:12 AM |
| Arbutus to Present HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)
globenewswire.com - October 3 at 3:06 PM |
| Arbutus to Present HBV Data at 2017 AASLD Liver Meeting
finance.yahoo.com - October 3 at 3:06 PM |
 | $116M deal for Bucks County company working on hepatitis B cure
www.bizjournals.com - October 2 at 3:11 PM |
| Arbutus Biopharma (ABUS) Receives $116M Strategic Investment from Roivant Sciences
www.streetinsider.com - October 2 at 3:10 PM |
| Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4
finance.yahoo.com - October 2 at 3:10 PM |
| Arbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - October 2 at 3:10 PM |
| Arbutus to Receive $116 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 2 at 3:10 PM |
| Roivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna
finance.yahoo.com - October 2 at 3:10 PM |
| Head to Head Comparison: Arbutus Biopharma Corporation (ABUS) and Its Peers
www.americanbankingnews.com - October 2 at 12:22 PM |
| Analysts Expect Arbutus Biopharma Corporation (ABUS) to Announce -$0.38 EPS
www.americanbankingnews.com - September 26 at 10:10 PM |
 | Arbutus Presents HBV Data at Upcoming Scientific Conferences
feeds.benzinga.com - September 22 at 5:49 PM |
| William Blair Weighs in on Arbutus Biopharma Corporation's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - September 22 at 9:00 AM |
| Arbutus Biopharma Corporation's (ABUS) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - September 20 at 8:20 PM |
| Is It Too Late To Buy Arbutus Biopharma Corporation (ABUS)?
finance.yahoo.com - September 20 at 3:19 PM |
| Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
finance.yahoo.com - September 20 at 3:19 PM |
| Arbutus Biopharma: Updates To Thesis - Seeking Alpha
seekingalpha.com - September 18 at 8:35 PM |
| Arbutus Biopharma Corporation (ABUS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 3:10 PM |
| Arbutus Biopharma Corporation (ABUS) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - September 17 at 1:20 AM |
| Arbutus Biopharma Corporation's (ABUS) "Buy" Rating Reiterated at Chardan Capital
www.americanbankingnews.com - September 16 at 7:18 AM |
| Company Spotlight: Arbutus Biopharma
www.rttnews.com - September 16 at 1:32 AM |
 | Company Spotlight: Arbutus Biopharma - Nasdaq
www.nasdaq.com - September 15 at 3:28 PM |
| Alexion to Restructure Operations, to Lower Headcount by 20% - Nasdaq
www.nasdaq.com - September 13 at 8:31 PM |
| Alexion to Restructure Operations, to Lower Headcount by 20%
finance.yahoo.com - September 13 at 8:31 PM |
| Arbutus: Potential Near-Term Catalysts and Pipeline Overview
finance.yahoo.com - September 12 at 3:23 PM |
| Arbutus to Host Live Webinar on Developments of LNP Delivery for mRNA-based Therapeutics
finance.yahoo.com - September 7 at 3:19 PM |
| Arbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 3:22 PM |
| Trading Arbutus Ahead Of Hepatitis B Data - Seeking Alpha
seekingalpha.com - August 22 at 8:41 PM |
| $790,000.00 in Sales Expected for Arbutus Biopharma Corporation (ABUS) This Quarter
www.americanbankingnews.com - August 22 at 11:40 AM |
| Insider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:48 PM |
| Arbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 16 at 8:23 PM |
| Arbutus to Present at 2017 Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 14 at 3:28 PM |
| Arbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 14 at 3:28 PM |
| Arbutus Biopharma Corporation (NASDAQ:ABUS) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - August 7 at 8:00 AM |
| Arbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 8:29 PM |
| Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 3:24 PM |
Arbutus Biopharma Corporation (ABUS) Chart for Saturday, October, 21, 2017
